Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-based Tests for Early Cancer Detection

BLOODPAC’s Early Detection and Screening (ED&S) Working Group has published its latest paper, titled "Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-based Tests for Early Cancer Detection." This publication builds on the important discussions from our AACR 2024 session, “Rethinking Cancer Risk and Risk Assessment for Liquid Biopsy-Based Single- and Multi-Cancer Screening,” and highlights the ongoing efforts of the Working Group.

The article captures the Working Group’s discussions on:

 1) risk assessment including considerations for adapting historical SCD risk terminology, such as “average risk” and “elevated risk” to MCD tests; 

2) the implications of this terminology for describing intended use populations; and

3) the existing gaps in evidence for determination of absolute risks.

Click here for the full article.

Previous
Previous

Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons

Next
Next

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium